Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Active OTC stocks -- Ignore unavailable to you. Want to Upgrade?

To: Bram12345 who wrote (857)	9/16/1998 8:01:00 PM
From: R>G>	Read Replies (1) \| Respond to of 1058

Subject Sangunie SGNC to be on CNNfn 9/21/98 8:30 PM E Sangunie is in the synthetic blood industry. Thomas C. Drees, Ph.D., M.B.A. is the chairman and CEO. He will be televised from 8:30-9:00 on Monday. The 1/2 hour program will focus on Sanguine, its product and the synthetic blood industry. Sangunie is filing with SEC Battelle is doing research and soon to start animal testing. This is a 2nd generation drug, the 1st generation drug had received FDA approval. Presently there are 60 million transfusions done per year. Average transfusion requires 2 pints. That's 120 million pints per year. Sanguine plans to sell product for $300.00 per pint. What percentage of this 36 billion market Sanguine will receive is too early to tell. This market is certainly large enough for more than one company. For more information please see R>G>s unofficial SGNC webpage members.aol.com